
Agenus Reports Positive Phase 2 BOT+BAL Results in Resectable Colon Cancer Published in Nature Medicine
Agenus Reports Promising Phase 2 UNICORN Trial Results for Neoadjuvant Botensilimab and Balstilimab in Resectable Colon Cancer Published in Nature Medicine Agenus Inc., a biotechnology company focused on developing innovative…













